A 60-year-old man with a heavy smoking history presents with a persistent cough and a central lung lesion near the right hilum and hypercalcemia. Which diagnosis is most likely?

Prepare for your CVP and GI Pathology Exam. Study using flashcards and multiple choice questions with hints and explanations to excel in your test.

Multiple Choice

A 60-year-old man with a heavy smoking history presents with a persistent cough and a central lung lesion near the right hilum and hypercalcemia. Which diagnosis is most likely?

Explanation:
Central, hilar-located lung tumors in heavy smokers point to squamous cell carcinoma. This cancer tends to arise in the bronchial epithelium and often presents as a central mass near the hilum. A hallmark paraneoplastic feature is hypercalcemia, usually from tumor production of PTH-related peptide (PTHrP) that increases calcium release from bone and calcium reabsorption in the kidneys. In contrast, adenocarcinoma is more likely peripheral and common in non-smokers; bronchioalveolar-type lesions are typically peripheral and have different imaging features, and hamartomas are benign lesions with characteristic calcifications and do not cause hypercalcemia. Thus, the combination of a central, hilar location and hypercalcemia best fits squamous cell carcinoma.

Central, hilar-located lung tumors in heavy smokers point to squamous cell carcinoma. This cancer tends to arise in the bronchial epithelium and often presents as a central mass near the hilum. A hallmark paraneoplastic feature is hypercalcemia, usually from tumor production of PTH-related peptide (PTHrP) that increases calcium release from bone and calcium reabsorption in the kidneys.

In contrast, adenocarcinoma is more likely peripheral and common in non-smokers; bronchioalveolar-type lesions are typically peripheral and have different imaging features, and hamartomas are benign lesions with characteristic calcifications and do not cause hypercalcemia. Thus, the combination of a central, hilar location and hypercalcemia best fits squamous cell carcinoma.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy